4.4 Review

Biosimilar safety factors in clinical practice

期刊

SEMINARS IN ARTHRITIS AND RHEUMATISM
卷 44, 期 6, 页码 S9-S15

出版社

W B SAUNDERS CO-ELSEVIER INC
DOI: 10.1016/j.semarthrit.2015.04.005

关键词

Chronic inflammatory diseases; Biosimilar; biologic; reference product; chronic inflammatory diseases; safety; interchangeability; comparability; immunogenicity; extrapolation; pharmacokinetics; pharmacodynamics; pharmacovigilance/surveillance; regulatory requirements; naming/labeling

向作者/读者索取更多资源

Objectives: This article provides insight into the guidelines issued by the European Medicines Agency (EMA) and the draft guidances issued by the US Food and Drug Administration (FDA) regarding potential safety considerations associated with the development and use of biosimilars. Methods: EMA and FDA guidelines and the literature were reviewed to identify recommendations and experience of manufacturers regarding the safety of biosimilars. Results: Recent results of phase 3 comparability clinical trials comparing biosimilars with their reference products, and the approval of a biosimilar infliximab by several regulatory agencies, demonstrate the growing importance of biosimilars in inflammatory diseases. The safety profiles of biosimilars developed according to regulatory guidelines appear to be highly similar to the reference product, and postmarketing pharmacovigilance programs are in place. Additional topics related to biosimilars, such as interchangeability, automatic substitution, and nomenclature, are discussed. Conclusions: Safety considerations in the development of biosimilars are an important focus of regulatory guidelines, although topics such as interchangeability, automatic substitution, and nomenclature are still being debated. (C) 2015 The Authors. Published by Elsevier HS Journals, Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.4
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据